Treatment Approaches for Metastatic NSCLC
| Start Date |
Wednesday, July 8, 2009 |
| End Date |
Wednesday, July 8, 2009 |
| Description |
Lung cancer is the leading cause of cancer related mortality in the United States in both men and women. NSCLC accounts for approximately 87% of all new lung cancer diagnoses and the majority of patients either present with incurable disease or relapse after curative therapy leading to the dismal 5 year survival of only 16%.
The management of metastatic NSCLC has evolved a great deal over the last decade and novel therapeutics, combined with chemotherapy, are now the standard of care for patients with newly diagnosed disease. In addition, we have learned a great deal about the role of tumor histology and cancer genetics in predicting responses to both standard chemotherapy and novel agents. Lastly, the role of second line chemotherapy is expanding as we are discovering the potential benefits of its earlier administration. |
| Contact Name |
Glenn Laudenslager |
| Phone |
1 203-840-5446 |
| E-mail |
tcorvi@reedexpo.com |
| Website |
http://www.mghacademy.org/events/details/?eventid=272 |
| Format |
Teleconference |
| Credit Hours |
1 |
| Credit Category |
AMA |
| Price |
FREE |
| Register by date |
Wednesday, July 8, 2009 |
| Specialties |
Oncology |
|